Lab results are too important to go anywhere else

Beaumont Laboratory

BCR/ABL Quantitation by RT-PCR

BCR Quantitation By RT-PCR, EPIC: LAB6390, SOFT: GQBCG


Samples should be drawn as early in the day as possible, so they can be delivered to the Laboratory the same day.

Specimen Collection Criteria

Collect: 10 mL whole blood in Lavender-top EDTA. (Min: 5.0 mL)

A copy of the requisition must be sent with the specimen. 

FedEx Shipping Instructions

Transport 10 mL whole blood (minimum: 5 mL), refrigerated. Do not freeze specimens.

Click here for complete shipping instructions.

Physician Office/Drawsite Specimen Preparation

Do not freeze specimens. Maintain whole blood at room temperature (20-26°C or 68-78.8°F),  or refrigerate (2-8°C or 36-46°F) if the specimen will not be received in the laboratory within 6 hours of collection.

Preparation for Courier Transport

Transport: Maintain whole blood at room temperature (20-26°C or 68-78.8°F) or refrigerate (2-8°C or 36-46°F) if the specimen will not be received in the laboratory within 6 hours of collection. (Min: 5.0 mL)

Rejection Criteria

  • Frozen specimens.
  • Unlabeled tubes.
  • Specimens collected in heparin (Green-top), clot tubes (Red-top), or SST tubes.


Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 6 hours
Refrigerated (2-8°C or 36-46°F): 48 hours
Frozen (-20°C/-4°F or below): Unacceptable

Specimen Storage in Department Prior to Disposal:

Refrigerated (2-8°C or 36-46°F): 7 days


Royal Oak Clinical Molecular Pathology Laboratory.


Once per week.
Results available within 7-14 days.

Reference Range

Negative (no gene rearrangement detected).

Test Methodology

RNA extraction and analysis for BCR-ABL fusion transcript from whole blood using reverse transcription - polymerase chain reaction (RT-PCR), with transcript quantitation by real-time PCR.


The BCR-ABL fusion transcript quantitation is normalized by calculating the relative ratio to normal ABL transcript. The presence of detectable BCR-ABL transcript confirms the existence of persistent transcriptionally active CML (chronic myeloid leukemia) cells.

Clinical Utility

  • This quantitative quantitative test is used for monitoring therapy response to tyrosine kinase inhibitors, by serial measurement of CML-specific transcripts (p210; b2a2, b3a2) as an accurate measure of the total leukemia-cell mass.
  • The test is recommended for all CML patients at 3 months intervals, per NIH consensus guidelines.

CPT Code


Test Codes


Last Updated


Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.

This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.